Section: Bilateral Contracts and Grants with Industry

Bilateral Grants with Industry

Implication in research for the development of Ebola vaccine has lead to several indirect contracts with industry:

• The EBOVAC1, EBOVAC2 and EBOVAC3 project, collaboration with Janssen from Johnson et Johnson.

• The BPZE-1 pertussis vaccine trial , which is presented in Section 'Bilateral Contracts with Industry', leads to collaboration with Iliad Biotechnologies.

• The Prevac trial vaccine trial leads to collaboration with Merck and Janssen. The purpose of this study is to evaluate the safety and immunogenicity of three vaccine strategies that may prevent Ebola virus disease (EVD) events in children and adults. Participants will receive either the Ad26.ZEBOV (rHAd26) vaccine with a MVA-BN-Filo (MVA) boost, or the rVSV$\Delta$G-ZEBOV-GP (rVSV) vaccine with or without boosting, or placebo.